Lyell Immunopharma to Participate in BofA Securities Health Care Conference
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‐stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT.
加利福尼亚州南旧金山，2024年5月7日（GLOBE NEWSWIRE）——临床阶段T细胞重编程公司莱尔免疫药业公司（纳斯达克股票代码：LYEL）今天宣布，其高级管理团队成员将于太平洋时间5月14日星期二上午8点40分参加美银证券2024年医疗保健会议。
A live webcast of the presentation can be accessed through the Investors section of the Company's website at . Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date.
可以通过公司网站的 “投资者” 部分观看该演讲的网络直播，网址为。现场演示结束后，网络直播的重播将在演示日期之后在公司网站上播放。
About Lyell Immunopharma, Inc.
关于 Lyell Immunopharma, Inc.
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Lyell is currently enrolling a Phase 1 clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) and a second Phase 1 clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit .
Lyell是一家临床阶段的T细胞重编程公司，致力于为实体瘤患者提供多样化的细胞疗法产品线。莱尔目前正在注册一项评估复发难治性三阴性乳腺癌（TNBC）和非小细胞肺癌（NSCLC）患者的ROR1靶向CAR T细胞疗法的1期临床试验，以及第二项评估晚期黑色素瘤、非小细胞肺癌和结直肠癌患者重编程肿瘤浸润淋巴细胞（TIL）的1期临床试验。为其候选产品提供动力的技术旨在解决限制实体瘤细胞疗法持续和长期反应的障碍：T细胞衰竭和缺乏耐久干性，包括持续和自我更新以推动持久肿瘤细胞毒性的能力。莱尔正在应用其专有的体外遗传和表观遗传学重编程技术来解决这些障碍，以开发具有更耐久临床效果的新药。Lyell总部位于加利福尼亚州南旧金山，在华盛顿州的西雅图和博塞尔设有工厂。要了解更多信息，请访问。
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
联系人：
艾伦·罗斯
传播与投资者关系高级副总裁
erose@lyell.com
译文内容由第三方软件翻译。